https://www.biopharmawatch.com/news/MIRM/fda-approval-atebrioz-zilurgisertib-fop BiopharmaWatch en 2026-09-26T10:07:00.000Z Samenvatting: Mirum Pharmaceuticals en Incyte maken bekend dat de Amerikaanse FDA goedkeuring heeft verleend voor Atebrioz™ (zilurgisertib) voor volwassen en pediatrische patiënten met fibrodysplasia ossificans progressiva https://www.biopharmawatch.com/news/MIRM/riassunto-mirum-pharmaceuticals-e-incyte-annunciano-l-approvazione-da-parte BiopharmaWatch en 2026-09-26T10:07:00.000Z Riassunto: Mirum Pharmaceuticals e Incyte annunciano l’approvazione da parte dell’FDA statunitense di Atebrioz™ (zilurgisertib) per pazienti adulti e pediatrici affetti da fibrodisplasia ossificante progressiva (FOP) https://www.biopharmawatch.com/news/MIRM/mirum-incyte-fda-approval-zilurgisertib-fop BiopharmaWatch en 2026-09-26T10:06:00.000Z Resumen: Mirum Pharmaceuticals e Incyte anuncian que Atebrioz™ (zilurgisertib) obtuvo la aprobación de la FDA de los EE. UU. para pacientes adultos y pediátricos con fibrodisplasia osificante progresiva https://www.biopharmawatch.com/news/MIRM/mirum-incyte-fda-approval-atebrioz-fop BiopharmaWatch en 2026-09-25T23:00:00.000Z Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva https://www.biopharmawatch.com/news/KOD/kodiak-sciences-daybreak-phase-3-results BiopharmaWatch en 2026-09-25T22:01:00.000Z Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration https://www.biopharmawatch.com/news/MBOT/microbot-medical-growth-strategy-highlights BiopharmaWatch en 2026-09-25T21:30:00.000Z Microbot Medical® Highlights Growth Strategy https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-nyse-notification-equity-deficiency BiopharmaWatch en 2026-09-25T21:04:19.755Z Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency https://www.biopharmawatch.com/news/MRK/ifinatamab-deruxtecan-bla-withdrawn-es-sclc BiopharmaWatch en 2026-09-25T20:30:00.000Z Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn https://www.biopharmawatch.com/news/NRSN/neurosense-business-update-progress-2026 BiopharmaWatch en 2026-09-25T20:30:00.000Z NeuroSense Provides Business Update and Progress for the First Half of 2026 https://www.biopharmawatch.com/news/NGEN/nervgen-restates-financial-statements-non-cash-adjustments BiopharmaWatch en 2026-09-25T20:30:00.000Z NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-proposed-settlement-derivative-action BiopharmaWatch en 2026-09-25T20:05:00.000Z Acadia Healthcare Provides Notice of Proposed Derivative Action Settlement https://www.biopharmawatch.com/news/ACET/adicet-bio-webcast-prula-cel-clinical-data BiopharmaWatch en 2026-09-25T20:00:00.000Z Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis https://www.biopharmawatch.com/news/MBRX/annamycin-cold-pancreatic-tumors-hot-aacr BiopharmaWatch en 2026-09-25T17:05:26.000Z Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR https://www.biopharmawatch.com/news/SLS/sellas-sls009-preclinical-data-pancreatic-cancer BiopharmaWatch en 2026-09-25T17:00:00.000Z SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer https://www.biopharmawatch.com/news/DVLT/datavault-ai-lawsuit-deadline-approaching BiopharmaWatch en 2026-09-25T16:05:00.000Z Datavault AI Inc. (NASDAQ: DVLT) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit https://www.biopharmawatch.com/news/HDB/hdb-alert-hagens-berman-national-trial-attorneys-encourages-hdfc-bank BiopharmaWatch en 2026-09-25T16:04:00.000Z HDB ALERT: Hagens Berman, National Trial Attorneys, Encourages HDFC Bank Limited (NYSE: HDB) Investors to Contact its Legal Team Regarding Securities Fraud Class Action Lawsuit https://www.biopharmawatch.com/news/DAVA/endava-plc-cfo-leave-stock-drop-investigation BiopharmaWatch en 2026-09-25T15:53:00.000Z Endava plc (NYSE: DAVA) Scrutinized Amid Board Placing CFO On Leave, 25% Stock Drop -- HBSS https://www.biopharmawatch.com/news/ONMD/onemednet-reverse-stock-split-september-2026 BiopharmaWatch en 2026-09-25T15:50:00.000Z OneMedNet Corporation Announces 1-for-10 Reverse Stock Split https://www.biopharmawatch.com/news/MEDP/overcoming-barriers-rare-disease-recruitment BiopharmaWatch en 2026-09-25T15:07:55.000Z Overcoming the Greatest Barriers in Rare Disease Patient Recruitment https://www.biopharmawatch.com/news/MEDP/recruiting-undiagnosed-population-considerations BiopharmaWatch en 2026-09-25T14:42:05.000Z Four Key Considerations for Recruiting an Undiagnosed Population https://www.biopharmawatch.com/news/PHAR/pharming-fda-acceptance-priority-review-joenja-apds BiopharmaWatch en 2026-09-25T14:30:00.000Z Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-zenbexus-results-excaliber-rrmm BiopharmaWatch en 2026-09-25T14:00:00.000Z Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma https://www.biopharmawatch.com/news/PNR/pentair-class-action-lawsuit-deadline-october-2026 BiopharmaWatch en 2026-09-25T13:41:00.000Z DEADLINE APPROACHING: Berger Montague Advises Pentair (NYSE: PNR) Investors to Inquire About a Securities Fraud Class Action by October 2, 2026 https://www.biopharmawatch.com/news/IART/integra-lifesciences-cusa-20-years-education-acs-congress BiopharmaWatch en 2026-09-25T13:05:00.000Z Integra LifeSciences Marks 20 Years of CUSA® Technology with Liver Surgery Education at ACS Clinical Congress 2026 https://www.biopharmawatch.com/news/IVF/invo-fertility-lytham-partners-fall-2026-conference BiopharmaWatch en 2026-09-25T13:00:00.000Z INVO Fertility to Participate in the Lytham Partners Fall 2026 Investor Conference https://www.biopharmawatch.com/news/TLRY/tilray-brands-q1-fiscal-results-october-2026 BiopharmaWatch en 2026-09-25T13:00:00.000Z Tilray Brands to Announce First Quarter Fiscal Year 2027 Financial Results on October 8, 2026 https://www.biopharmawatch.com/news/SBC/sbc-medical-investor-conferences-october-2026 BiopharmaWatch en 2026-09-25T13:00:00.000Z SBC Medical to Participate in Several Upcoming Investor Conferences in October 2026 https://www.biopharmawatch.com/news/RHEL/rhelion-expands-agreement-university-chieti-pescara BiopharmaWatch en 2026-09-25T12:48:00.000Z Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resistant Depression in Italy https://www.biopharmawatch.com/news/MUSQ/musq-global-music-industry-etf-liquidation BiopharmaWatch en 2026-09-25T12:30:00.000Z Exchange Traded Concepts to Close and Liquidate The MUSQ Global Music Industry Index ETF (NYSE: MUSQ) https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-presentations-world-muscle-society BiopharmaWatch en 2026-09-25T12:30:00.000Z Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress https://www.biopharmawatch.com/news/TDOC/teladoc-health-chief-legal-officer-transition BiopharmaWatch en 2026-09-25T12:30:00.000Z Teladoc Health Announces Chief Legal Officer Transition https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-mrd-testing-definition-cure BiopharmaWatch en 2026-09-25T12:03:00.000Z Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure https://www.biopharmawatch.com/news/CHER/cheelcare-q1-fiscal-2027-financial-results BiopharmaWatch en 2026-09-25T12:00:00.000Z Cheelcare Announces First Quarter Fiscal 2027 Financial Results https://www.biopharmawatch.com/news/IZO/izotropic-announces-private-placement BiopharmaWatch en 2026-09-25T12:00:00.000Z Izotropic Announces Non-Brokered Private Placement https://www.biopharmawatch.com/news/QTRX/quanterix-spatial-biology-innovation-essb-2026 BiopharmaWatch en 2026-09-25T12:00:00.000Z Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026 https://www.biopharmawatch.com/news/COR/cencora-elects-robert-sanchez-board-directors BiopharmaWatch en 2026-09-25T12:00:00.000Z Cencora Elects Robert E. Sanchez to Its Board of Directors https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-china-strategy-growth BiopharmaWatch en 2026-09-25T12:00:00.000Z Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-neurosigma-partner-pediatric-adhd BiopharmaWatch en 2026-09-25T11:45:00.000Z Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD https://www.biopharmawatch.com/news/CNSY/cerenome-cnside-business-update-call-september-2026 BiopharmaWatch en 2026-09-25T11:30:00.000Z Cerenome to Hold CNSide® Business Update Call on September 30, 2026 https://www.biopharmawatch.com/news/OCGN/ocugen-provisional-approval-ocu400-retinitis-pigmentosa BiopharmaWatch en 2026-09-25T11:02:00.000Z Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa https://www.biopharmawatch.com/news/UTMD/utah-medical-products-tender-offer-expiration-date BiopharmaWatch en 2026-09-25T11:00:00.000Z Utah Medical Products, Inc. Clarifies Tender Offer Expiration Date https://www.biopharmawatch.com/news/FATE/fate-therapeutics-cirm-grant-reclaim-ln-trial BiopharmaWatch en 2026-09-25T11:00:00.000Z Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-cemsidomide-phase-1-trial-data BiopharmaWatch en 2026-09-25T11:00:00.000Z C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting https://www.biopharmawatch.com/news/LEGN/legend-biotech-carvykti-five-year-data-rrmm BiopharmaWatch en 2026-09-25T11:00:00.000Z Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion https://www.biopharmawatch.com/news/VICP/vicapsys-advisory-board-stateline-merger BiopharmaWatch en 2026-09-25T10:05:00.000Z Vicapsys Life Sciences Announces Advisory Board Following Completion of Stateline Merger https://www.biopharmawatch.com/news/MEDS/datameds-ai-presentation-national-telehealth-summit BiopharmaWatch en 2026-09-25T06:00:00.000Z DataMEDS AI To Present At 2026 National Telehealth and Virtual Care Summit https://www.biopharmawatch.com/news/RGNX/regenxbio-three-year-data-surabgene-lomparvovec BiopharmaWatch en 2026-09-24T23:17:00.000Z REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-alzheimers-treatment-study BiopharmaWatch en 2026-09-24T22:51:00.000Z Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment https://www.biopharmawatch.com/news/MDP/medexus-annual-meeting-shareholders-election-directors BiopharmaWatch en 2026-09-24T21:30:00.000Z Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors https://www.biopharmawatch.com/news/EHC/encompass-health-expansion-montgomery-county-texas BiopharmaWatch en 2026-09-24T20:30:00.000Z Encompass Health expands in Montgomery County, Texas, with first small-format hospital, replacement hospital https://www.biopharmawatch.com/news/MDAI/spectral-ai-presentation-acs-clinical-congress-2026 BiopharmaWatch en 2026-09-24T20:15:00.000Z Spectral AI Announces Upcoming Presentation at ACS Clinical Congress 2026 Highlighting the Use of Artificial Intelligence and Multi-Spectral Imaging in the Assessment of Burn Wounds https://www.biopharmawatch.com/news/NBTX/nanobiotix-first-half-2026-update BiopharmaWatch en 2026-09-24T20:15:00.000Z NANOBIOTIX Provides First Half 2026 Operational and Financial Update https://www.biopharmawatch.com/news/QGEN/qiagen-launches-qiamini-automate-sample-preparation BiopharmaWatch en 2026-09-24T20:05:00.000Z QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation https://www.biopharmawatch.com/news/RZLT/rezolute-fiscal-2026-results-business-update BiopharmaWatch en 2026-09-24T20:05:00.000Z Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-stifel-2026-forum BiopharmaWatch en 2026-09-24T20:05:00.000Z Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum https://www.biopharmawatch.com/news/STAA/staaar-surgical-share-repurchase-authorization BiopharmaWatch en 2026-09-24T20:01:00.000Z STAAR Surgical Board Approves $50 Million Share Repurchase Authorization https://www.biopharmawatch.com/news/IMCC/im-cannabis-closes-1-31-million-offering BiopharmaWatch en 2026-09-24T20:01:00.000Z IM Cannabis Announces Closing of US$1.31 Million Registered Direct Offering of Common Shares https://www.biopharmawatch.com/news/PRME/prime-medicine-fda-clearance-pm647-aatd BiopharmaWatch en 2026-09-24T20:01:00.000Z Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency https://www.biopharmawatch.com/news/COAG/hemab-therapeutics-appoints-keli-walbert-board BiopharmaWatch en 2026-09-24T20:01:00.000Z Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert https://www.biopharmawatch.com/news/ABBV/uchicago-medicine-abbvie-cancer-pavilion-construction-complete BiopharmaWatch en 2026-09-24T19:07:00.000Z UChicago Medicine completes construction phase of AbbVie Foundation Cancer Pavilion, bringing new era of cancer care closer to reality https://www.biopharmawatch.com/news/VMD/viemed-healthcare-automatic-securities-disposition-plan BiopharmaWatch en 2026-09-24T18:30:00.000Z Viemed Healthcare Announces Adoption of Automatic Securities Disposition Plan by President Michael Moore https://www.biopharmawatch.com/news/PRTH/investigation-priority-technology-holdings-sale BiopharmaWatch en 2026-09-24T18:04:00.000Z $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Priority Technology Holdings, Inc. (NASDAQ: PRTH) https://www.biopharmawatch.com/news/PLUN/investigation-plutonian-acquisition-corp-merger BiopharmaWatch en 2026-09-24T18:02:00.000Z SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Plutonian Acquisition Corp II (NYSE: PLUN)